PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
35.81%
Positive EBIT growth while CRVO is negative. John Neff might see a substantial edge in operational management.
36.41%
Positive operating income growth while CRVO is negative. John Neff might view this as a competitive edge in operations.
439.57%
Positive net income growth while CRVO is negative. John Neff might see a big relative performance advantage.
440.81%
Positive EPS growth while CRVO is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
440.81%
Positive diluted EPS growth while CRVO is negative. John Neff might view this as a strong relative advantage in controlling dilution.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
681.03%
Positive OCF growth while CRVO is negative. John Neff would see this as a clear operational advantage vs. the competitor.
681.03%
Positive FCF growth while CRVO is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1209.68%
OCF/share CAGR of 1209.68% while CRVO is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
1209.68%
OCF/share CAGR of 1209.68% while CRVO is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
1209.68%
Positive 3Y OCF/share CAGR while CRVO is negative. John Neff might see a big short-term edge in operational efficiency.
934.70%
10Y net income/share CAGR of 934.70% while CRVO is zero. Bruce Berkowitz would see if minor gains can compound into a bigger lead over time.
934.70%
Net income/share CAGR of 934.70% while CRVO is zero. Bruce Berkowitz would see if small mid-term gains can develop into a bigger lead.
934.70%
Positive short-term CAGR while CRVO is negative. John Neff would see a clear advantage in near-term profit trajectory.
-244.00%
Negative equity/share CAGR over 10 years while CRVO stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-244.00%
Negative 5Y equity/share growth while CRVO is at 0.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-244.00%
Negative 3Y equity/share growth while CRVO is at 52029.72%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
2826.88%
Asset growth above 1.5x CRVO's 9.82%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
26.94%
BV/share growth above 1.5x CRVO's 16.26%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
3.22%
We have some new debt while CRVO reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
No Data
No Data available this quarter, please select a different quarter.
-10.82%
We cut SG&A while CRVO invests at 52.67%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.